Structure-guided design of small-molecule therapeutics against RSV disease

Abstract excerpt

INTRODUCTION: In the United States, respiratory syncytial virus (RSV) is responsible for the majority of infant hospitalizations resulting from viral infections, as well as a leading source of pneumonia and bronchiolitis in young children and the elderly. In the absence of vaccine prophylaxis or an effective antiviral for improved disease management, the development of novel anti-RSV therapeutics is critical....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Pneumonia and Respiratory Infections
• Share to Respiratory viral infections research
• Share to Viral gastroenteritis research and epidemiology